RecruitingNCT07021911

Concomitant Radiotherapy and New Drugs in Metastatic Breast Cancer


Sponsor

Fondazione Policlinico Universitario Campus Bio-Medico

Enrollment

300 participants

Start Date

May 17, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

The primary objective of the study is to describe the tolerance profile of radiation treatments performed during systemic treatment with new drugs (molecular targeted therapies, immunotherapy, others).


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at how radiation therapy works alongside various modern systemic cancer treatments (such as targeted therapies, immunotherapy, or antibody-drug conjugates) in patients with stage IV (metastatic) breast cancer, to better understand safety and effectiveness when the two are combined. **You may be eligible if...** - You have stage IV (metastatic) breast cancer - You are currently receiving a systemic treatment such as targeted therapy, immunotherapy, an antibody-drug conjugate, or a tyrosine kinase inhibitor - You are a candidate for radiation therapy (for symptom relief or local control) **You may NOT be eligible if...** - The area being considered for radiation has been previously irradiated - You have an absolute medical contraindication to radiation - Your systemic treatment is part of a separate clinical trial Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONRadiotherapy

Conventional fractionated radiotherapy, moderate hypofractionated radiotherapy, stereotactic radiotherapy (SABR)


Locations(1)

Radiation Oncology Department Fondazione Policlinico Campus BioMedico

Rome, Italy, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07021911


Related Trials